Changing patterns of Kaposi's sarcoma in Nigerians

2005 ◽  
Vol 35 (3) ◽  
pp. 168-169 ◽  
Author(s):  
A Z Mohammed ◽  
E J C Nwana ◽  
A N Manasseh
Keyword(s):  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
University Teaching ◽  
Hiv Positive ◽  
Antibody Testing ◽  
African Countries ◽  
The Face ◽  
Changing Patterns ◽  
Hiv Antibody Testing ◽  
Hiv Negative

This is a five-year retrospective study of 32 histologically diagnosed cases of Kaposi's sarcoma (KS) who had undergone HIV antibody testing at the Jos University Teaching Hospital: 13 cases (40%) were HIV-negative. Multiple lesions were more common in HIV-positive cases and affected unusual sites such as the face, oropharynx, conjuctiva, vulva and rectum in addition to the limbs and trunk, which were more frequently involved in HIV-negative cases. This pattern of KS seen in Nigerian patients shows similarities with other African countries which have been affected by the HIV epidemic.

scholarly journals Simultaneous Association of Pulmonary Tuberculosis and Kaposi’s Sarcoma in an Immunocompetent Subject: A Case Report and Literature Review

2019 ◽  
Vol 2019 ◽  
pp. 1-3
Author(s):  
Sofia Baina ◽  
Jihane Achrane ◽  
Jouda Benamor ◽  
Jamal Eddine Bourkadi
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Pulmonary Tuberculosis ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Hiv Positive ◽  
Negative Patient ◽  
Different Types ◽  
Hiv Negative

Kaposi’s Sarcoma (KS) occurs as a pathological entity that may be classified into four different types: classic, endemic, epidemic, and iatrogenic. It can arise among HIV-positive subjects or within immunosuppression, yet exceptionally of tuberculous origin. We describe a new case report of an HIV-negative patient, manifesting Kaposi’s disease in the course of tuberculosis, with the aim to assess this uncommon disorder and to outline this rare atypical association.

Evaluation of microalbumin, cystatin c, creatinine and uric acid levels in HIV patients in Nnamdi Azikiwe University Teaching Hospital, Nnewi

2021 ◽  
Vol 8 (3) ◽  
pp. 132-142
Author(s):  
Ezeugwunne Ifeoma Priscilla ◽  
Amaifeobu Clement ◽  
Meludu Samuel Chukwuemeka ◽  
Analike Rosemary Adamma ◽  
Nnamdi Johnjude Chinonso ◽  
...  
Keyword(s):  
Uric Acid ◽  
Cystatin C ◽  
Teaching Hospital ◽  
University Teaching ◽  
Hiv Positive ◽  
Hiv Patients ◽  
Voluntary Counseling And Testing ◽  
Group B ◽  
And Control ◽  
Hiv Negative

This study evaluated the microalbumin, cystatin C, creatinine and uric acid levels in HIV patients in Nnamdi Azikiwe University Teaching Hospital, Nnewi (NAUTH). A total of one hundred (100) male and female HIV positive and control participants who were aged between 18 and 60 years attending the voluntary counseling and testing unit (VCT) and antiretroviral therapy unit (ART) of NAUTH were randomly recruited for the study and grouped thus: Group A (HIV positive symptomatic participants on long term ART (HPSPLTART) (n= 25); Group B (HIV positive symptomatic participants on short term ART (HPSPSTART) (n= 25); Group C: Asymptomatic HIV positive participants NOT on ART (AHPPNART) (n=25) and Group D: control (n=25).6mls of blood sample and 10mls of freshly voided urine samples were collected from each of the participants for the evaluation of biochemical parameters using standard laboratory methods. Results showed significantly higher BMI and SBP in HPSPSTART than in control (p=0.04; 0.02). SBP was significantly higher in HPSPLTART than in AHPPNART and Control (p=0.00). DBP was significantly higher in HPSPLTART than in HPSPSTART and control respectively (p=0.00). There were significantly higher plasma creatinine and Cys-C levels in both male HIV positives and male HIV positive participants on ART than in both females respectively (p0.00; 0.02). Also, BMI, creatinine, uric acid and Cystatin C levels were significantly higher in male HIV negative participants than in female HIV negative participants (p=0.00; 0.04; 0.02; 0.01). This study has revealed greater risk for renal disease among the HIV participants studied.

scholarly journals Therapeutic Outcomes in AIDS-Associated Kaposi's Sarcoma Patients on Antiretroviral Therapy Treated with Chemotherapy at Two Tertiary Hospitals in Lusaka, Zambia

2018 ◽  
Vol 16 (3) ◽  
pp. 231-236 ◽  
Author(s):  
Watson Mtonga ◽  
Aaron Mujajati ◽  
Derick Munkombwe ◽  
Aubrey Kalungia ◽  
Lungwani Tyson Muungo ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Complete Response ◽  
University Teaching ◽  
Teaching Hospitals ◽  
Recurrence Rates ◽  
Therapeutic Outcomes ◽  
Efficacious Treatment ◽  
Study Participants

The incidence of HIV-associated Kaposi’s sarcoma (KS) remains high in Zambia in the antiretroviral therapy era. The most efficacious treatment regimen for KS has yet to be established. In both developed and developing countries, treatment regimens have had limited efficacy. Late presentation in Africa affects therapeutic outcomes. Objective: The aim of this study was to determine therapeutic outcomes of epidemic KS patients on combination antiretroviral therapy (cART) after completion of six cycles of Adriamycin, Bleomycin, and Vincristine (ABV) chemotherapy. Methods: This was a descriptive cross-sectional study. Study participants were drawn from a study database of confirmed incident KS patients seen at the Skin Clinic of the University Teaching Hospitals (UTH) during the period between August, 2015 and September, 2016. Results: Of the 38 successfully recruited study participants, a complete response was documented in 18 (47%) after 6 cycles of ABV whereas 20 (53%) experienced a partial response. KS recurrence was observed in 8 (44%) of the individuals that experienced an initial complete response. At the time of the study, clinical assessment revealed that KS lesions had completely regressed in 21 (55%) of all the patients. Conclusion: ABV chemotherapy appears ineffective in long-term resolution of epidemic KS patients on ART. Recurrence rates are high after chemotherapy in patients that experience initially favorable responses to treatment. There is a need to diagnose KS earlier, and to develop more efficacious treatment options in order to reduce recurrence rates for epidemic KS.

scholarly journals Kaposi’s sarcoma in an HIV-negative patient

2016 ◽  
Vol 22 (12) ◽  
Author(s):  
Shields Callahan ◽  
Randie H Kim ◽  
Nooshin Brinster ◽  
Jo-Ann Latkowski
Keyword(s):  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Negative Patient ◽  
Hiv Negative

Hiv Negative Penile Kaposi's Sarcoma In Circumcised Men

2018 ◽  
Vol 28 (09) ◽  
pp. S222-S224
Author(s):  
Ahmet Urkmez ◽  
Serkan Akan ◽  
Emrah Ozsoy
Keyword(s):  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Hiv Negative

scholarly journals Kaposi’s sarcoma in an HIV-negative chronic lymphocytic leukemia patient without immunosuppressive therapy: A case report

2018 ◽  
Vol 6 ◽  
pp. 2050313X1879923
Author(s):  
Damir Vučinić ◽  
Andrea Dekanić ◽  
Gordana Zamolo ◽  
Margita Belušić-Gobić ◽  
Ingrid Belac-Lovasić ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Kaposi's Sarcoma ◽  
Human Herpesvirus ◽  
Kaposi’S Sarcoma ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Vascular Tumor ◽  
Lymphocytic Leukemia ◽  
Herpesvirus 8 ◽  
Mucous Membranes ◽  
Hiv Negative

Kaposi’s sarcoma is a neoplasm of endothelial cells. That vascular tumor is usually limited to the skin, but it may involve mucous membranes, visceral organs, and lymph nodes. Serological evidence has shown that human herpesvirus 8 infection is required for the development of Kaposi’s sarcoma. Chronic lymphocytic leukemia is the most common leukemia all over the world. Increased skin cancer risk has been reported for patients with chronic lymphocytic leukemia. The relation between these two pathologies has not yet been clarified. We report a case of Kaposi’s sarcoma along with chronic lymphocytic leukemia in a patient who did not receive therapy for chronic lymphocytic leukemia.

Sign in / Sign up

Export Citation Format

Share Document